The National Eye Institute (NEI) seeks research co-development or licensees for making research- or clinical-grade preservation solutions for cold-sensitive organ transplantation or protection of brain injury or trauma during surgery.
The National Eye Institute's Ophthalmic Genetics and Visual Function Branch seeks interested commercial parties to co-develop the use of nitisinone (NTBC) for oculocutaneous albinism or as a treatment for increasing pigmentation in the eyes, hair and/or skin of patients.
The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of induced pluripotent stem cells (IPS cells) derived from patients with CEP290 associated ciliopathies. IPS cells were derived from patients with Leber-congenital amaurosis and their unaffected relatives.
Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more selective estrogen-receptor modulators (SERMs), which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration (AMD). SERMs exert their specific protection on photoreceptor degeneration likely by inhibiting microglial activation.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for gene therapy for CRX retinopathies such as Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy.
The National Eye Institute (NEI) seek research co-development or licensees for advancing AAV8/9-based therapies for X-linked forms of retinitis pigmentosa (XLRP) caused by mutations in RPGR (retinitis pigmentosa GTPase regulator) or RP2 (retinitis pigmentosa 2) gene.
Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, which can be used to culture and image embryos. The chamber allows for the continuous imaging of the embryo for the culture period. NEI seeks research collaborations and/or licensees for the development of this culture and imaging chamber for murine embryos.
Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system.
Researchers at the National Eye Institute (NEI), have developed a cryopreservation and cell recovery system designed specifically for the efficient cryopreservation, transportation and subsequent thawing of monolayers and tissues on a substrate. This closed cryopreservation/defrost system allows for sterility in addition to increased viability, recovery and safety of tissues that can be used for in vitro culture or surgical transplantation.
Researchers at the National Eye Institute (NEI) developed a surgical tool to place tissue into position in the retina. The NEI seeks co-development or licensing to commercialize a prototype already in pre-manufacturing. Alternative uses will be considered.
The National Eye Institute (NEI) and National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS) seeks licensing and/or co-development of a method of producing human retinal pigment epithelial (RPE) cells from human induced pluripotent stem cells (iPSCs).
This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.
Researchers at the National Eye Institute (NEI) have generated Induced Pluripotent Stem Cells (iPS) from two Late-Onset Reginal (L-ORD) patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. All iPS cells were differentiated into authenticated Retinal Pigment Epithelium (RPE) cells. The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration.
Researchers at the National Eye Institute have developed a new cytokine therapy that delivers functional interleukin 34 (IL-34) to the retina for treating ocular inflammatory diseases – such as uveitis and degenerative retinal diseases. Intraocular delivery of IL-34 protein or IL-34 gene expression system can effectively prevent retinal inflammation. Thus, it may be a promising strategy to produce long-lasting effects in suppressing abnormal retinal inflammation and preventing photoreceptor death.
The National Eye Institute’s Ophthalmic Genetics and Visual Function Branch seeks partners to co-develop the protocol for iPSC to RPE differentiation and its use in clinical, screening and translational settings.